Request Appointment
622 West 168th StreetNew York, NY 10032
Overview of Dr. Mor
Dr. Adam Mor is a rheumatologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, NewYork-Presbyterian/Columbia University Irving Medical Center, and NYC Health + Hospitals / South Brooklyn Health. He received his medical degree from Tel Aviv University Sackler and has been in practice 18 years. He is one of 20 doctors at NYC Health + Hospitals / South Brooklyn Health and one of 117 doctors at New York-Presbyterian Hospital who specialize in Rheumatology. He has more than 100 publications and over 500 citings.
Education & Training
NYU Grossman School of MedicineResidency, Internal Medicine, 2009 - 2011- NYU Grossman School of MedicineFellowship, Rheumatology, 2003 - 2005
Tel Aviv University SacklerClass of 1999
Certifications & Licensure
NY State Medical License 2011 - 2026
NJ State Medical License 2013 - 2017
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Rheumatology
Publications & Presentations
PubMed
- Osteoarthritis increases the risk of inflammatory arthritis due to immune checkpoint inhibitors associated with tissue-resident memory T cells.Matthieu Paiola, Daniel M Portnoy, Luke Yi Hao, Shoiab Bukhari, Robert J Winchester
Journal for Immunotherapy of Cancer. 2025-03-21 - Changing the location of proteins on the cell surface is a promising strategy for modulating T cell functions.Marianne Strazza, Ruijiang Song, Shannon Hiner, Adam Mor
Immunology. 2024-10-01 - 2 citationsExclusion of PD-1 from the immune synapse: A novel strategy to modulate T cell function.Luke Yi Hao, Shalom Lerrer, Matthieu Paiola, Emily K Moore, Yevgeniya Gartshteyn
Molecular Therapy. Oncology. 2024-09-19
Journal Articles
- Review Targeting the Programmed Cell Death-1 Pathway in Rheumatoid ArthritisAdam Mor, Greg J. Silverman, Sabina Sandigursky, ScienceDirect
Press Mentions
“Double Life” of Key Immune Protein Reveals New Strategies for Treating Cancer and Autoimmune DiseasesMarch 10th, 2024- “Double Life” of Key Immune Protein Reveals New Strategies for Treating Cancer and Autoimmune DiseasesMarch 15th, 2024
Grant Support
- A systematic approach to uncover the basic mechanisms of checkpoint inhibitor immune related adverse eventsCOLUMBIA UNIVERSITY HEALTH SCIENCES2023–2027
- A systematic approach to uncover the basic mechanisms of checkpoint inhibitor immune related adverse eventsCOLUMBIA UNIVERSITY HEALTH SCIENCES2023–2027
- Novel mechanisms regulating PD-1 signaling and functionCOLUMBIA UNIVERSITY HEALTH SCIENCES2016–2027
- PAG is a novel target in immunotherapyCOLUMBIA UNIVERSITY HEALTH SCIENCES2020–2025
- PAG is a novel target in immunotherapyCOLUMBIA UNIVERSITY HEALTH SCIENCES2020–2025
- PAG is a novel target in immunotherapyCOLUMBIA UNIVERSITY HEALTH SCIENCES2020–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
